Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HR+/HER2- Breast Cancer × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 40 Endometrial Neoplasms 10 Polycystic Ovary Syndrome 4 Ovarian Neoplasms 3 Neoplasms 3 Fallopian Tube Neoplasms 3 Triple Negative Breast Neoplasms 2 Progesterone Resistance 2 Infertility, Female 2 Infertility 2 Endometrial Hyperplasia 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Intraductal, Noninfiltrating 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Obesity 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Locally Advanced Breast Cancer 1 Leiomyoma 1 Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1

Interventions

Letrozole 1 Fulvestrant 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡